Rapid Micro Biosystems (RPID) Current Deferred Revenue (2020 - 2026)

Rapid Micro Biosystems' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $6.6 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 8.34% year-over-year to $6.6 million; the TTM figure through Mar 2026 stood at $6.6 million (up 8.34% YoY), while the FY2025 annual figure was $4.7 million, down 28.26% from the prior year.
• Current Deferred Revenue came in at $6.6 million for Q1 2026 at Rapid Micro Biosystems, up from $4.7 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $6.6 million in Q1 2026 to a low of $3.4 million in Q3 2022.
• A 5-year average of $5.2 million and a median of $5.4 million in 2024 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 42.21% in 2022 and declined 28.26% in 2025, its largest moves.
• Rapid Micro Biosystems' Current Deferred Revenue stood at $4.7 million in 2022, then gained by 27.11% to $6.0 million in 2023, then increased by 10.46% to $6.6 million in 2024, then dropped by 28.26% to $4.7 million in 2025, then soared by 39.42% to $6.6 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $6.6 million, $4.7 million, and $5.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison